| Identification | Back Directory | [Name]
MCC950 | [CAS]
210826-40-7 | [Synonyms]
MCC950
CS-2292
CP-456773
MCC950
(MCC-950
1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea
N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamid
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide
N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide
2-Furansulfonamide, N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C20H24N2O5S | [MDL Number]
MFCD28900720 | [MOL File]
210826-40-7.mol | [Molecular Weight]
404.48 |
| Chemical Properties | Back Directory | [Melting point ]
239 °C | [density ]
1.396±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO (up to 40 mg/ml) or in Water (up to 30 mg/ml) | [form ]
solid | [pka]
4.74±0.10(Predicted) | [color ]
White | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 1 month. |
| Hazard Information | Back Directory | [Description]
MCC-950 (210826-40-7) was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1.1?Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes.2?MCC-950 blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations.3?Inhibits interleukin 1β (IL-1β) secretion?in vivo?and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model).3?Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome.4?MCC-950 is a valuable new tool for exploring the pathophysiology of NLRP3. | [Uses]
MCC950 selectively inhibits pyrin domain-containing protein 3 (NLRP3) inflammasome, a protein complex involved in the inflammatory process (1). The NLRP3 inflammasome is related to a wide range of immune disorders such as multiple sclerosis, inflammatory bowel disease, auto-immune and auto-inflammatory diseases (2). MCC950 has been shown to specifically inhibit the activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes (1). MCC950 is a potential therapeutic for NLRP3-associated syndromes. | [References]
1) Laliberte?et al.?(2003),?Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing; J. Biol. Chem.,?278?16567
2) Coll?et al. (2011),?The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes; Clin. PLoS One,?6(12)?e29539
3) Coll?et al.?(2015),?A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease; Nat. Med.,?21?248
4) Kaneko?et al.?(2015),?Reconstituted AIM2 inflammasome in cell-free system; J. Immunol. Methods,?426?76 |
|
| Company Name: |
Biokitchen Gold
|
| Tel: |
021-021-021-31663258 13795219287 |
| Website: |
http://www.is0513.com/ShowSupplierProductsList20174/0.htm |
|